Immunotherapy, predominantly immune-check point inhibitors (ICIs) enhance immune-mediated anticancer activity by blocking immune-attenuating interactions of CTLA-4/B7 or PD-1/PD-L1 receptors between T-lymphocytes and cancer cells (77). Here, CTLA4 is linked to cancer.